An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2018
At a glance
- Drugs TAK 931 (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Oncology
- 31 Aug 2018 Biomarkers information updated
- 17 Jul 2018 Planned number of patients changed from 88 to 160.
- 17 Jul 2018 Planned End Date changed from 22 Feb 2019 to 26 Aug 2020.